CEO Interview: Explore How Genetic Technologies is Revolutionizing Personalized Medicine with AI
Oct. 7, 2024
Genetic Technologies (NASDAQ: GENE) is turning cutting-edge science into personalized, predictive tests driven by AI and machine learning. Backed by over 20 years of experience, GENE’s scientific and clinical teams are translating genetics and clinical information into absolute risk tests that predict risk of chronic disease before onset, empowering physicians to improve health outcomes for people around the world enabling a new era of personalized medicine.
GENE is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, a first-in-class test that can predict a person’s risk in up to 70% of annual mortalities and morbidities before onset. In addition to its B2B model, GENE is also focused on expanding its directto- consumer testing programs. The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of +17%.
Visit www.redchip.com/stocks/GENE to learn more.
